Document Detail

Rituximab therapy in severe juvenile pemphigus vulgaris.
MedLine Citation:
PMID:  18038698     Owner:  NLM     Status:  MEDLINE    
Juvenile pemphigus vulgaris (PV) is a rare and often misdiagnosed condition. Although PV frequently is severe in children, a substantial portion of the morbidity and mortality associated with juvenile PV has been attributed to treatment. This report demonstrates the efficacy of rituximab therapy in juvenile PV. We report 2 cases and review the literature. Rituximab treatment was effective in helping to control 2 recalcitrant cases of juvenile PV without inducing the adverse effects associated with other adjuvant therapies. Rituximab should be considered when treating resistant cases of PV in pediatric populations to avoid the long-term side effects of other immunosuppressive treatments.
Adam J Mamelak; Mark P Eid; Bernard A Cohen; Grant J Anhalt
Related Documents :
18947688 - Recurrent priapism in the young patient treated with baclofen.
16442138 - Effects of predation pressure on species packing on a resource gradient: insights from ...
576528 - Five cases of absence of iodide concentrating mechanism.
1758778 - Centipede ingestion by a six-month-old infant: toxic side effects.
20430928 - Surgical adverse outcome reporting as part of routine clinical care.
24673138 - Metaphyseal osteopathy in three australian kelpie siblings.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Cutis     Volume:  80     ISSN:  0011-4162     ISO Abbreviation:  Cutis     Publication Date:  2007 Oct 
Date Detail:
Created Date:  2007-11-27     Completed Date:  2008-02-27     Revised Date:  2013-09-12    
Medline Journal Info:
Nlm Unique ID:  0006440     Medline TA:  Cutis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  335-40     Citation Subset:  IM    
Department of Dermatology, Johns Hopkins University, Baltimore, MD 21287, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Murine-Derived
Immunologic Factors / therapeutic use*
Pemphigus / drug therapy*,  pathology*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Murine-Derived; 0/Immunologic Factors; 0/rituximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Gender differences in dermatologists' annual incomes.
Next Document:  Short-term corticosteroids and avascular necrosis: medical and legal realities.